Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach

Dennyson Leandro M. Fonseca*, Igor Salerno Filgueiras, Alexandre H.C. Marques, Elroy Vojdani, Gilad Halpert, Yuri Ostrinski, Gabriela Crispim Baiocchi, Desirée Rodrigues Plaça, Paula P. Freire, Shahab Zaki Pour, Guido Moll, Rusan Catar, Yael Bublil Lavi, Jonathan I. Silverberg, Jason Zimmerman, Gustavo Cabral-Miranda, Robson F. Carvalho, Taj Ali Khan, Harald Heidecke, Rodrigo J.S. DalmolinAndre Ducati Luchessi, Hans D. Ochs, Lena F. Schimke, Howard Amital, Gabriela Riemekasten, Israel Zyskind, Avi Z. Rosenberg, Aristo Vojdani, Yehuda Shoenfeld, Otavio Cabral-Marques*

*Corresponding author for this work
1 Citation (Scopus)

Abstract

Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) severity due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, and chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health and disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 individuals with different COVID-19 severity (71 mild, 61 moderate, and 27 with severe symptoms) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multiple linear regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition and hierarchical clustering analysis based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe COVID-19 patients ≥50 years of age. Follow-up analysis using binomial logistic regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies significantly increased the likelihood of developing a severe COVID-19 phenotype with aging. These findings provide key insights to explain why aging increases the chance of developing more severe COVID-19 phenotypes.

Original languageEnglish
Article number21
Journalnpj Aging
Volume9
Issue number1
DOIs
Publication statusPublished - 12.2023

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

  • 204-05 Immunology
  • 205-18 Rheumatology

Coronavirus related work

  • Research on SARS-CoV-2 / COVID-19

Fingerprint

Dive into the research topics of 'Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach'. Together they form a unique fingerprint.

Cite this